GI
BCRX icon

GAMMA Investing’s BioCryst Pharmaceuticals BCRX Stock Holding History

GAMMA Investing’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.3K Buy
1,229
+11
+0.9% +$99 ﹤0.01% 3102
2026
Q1 		$11.6K Buy
1,218
+977
+405% +$7.59K ﹤0.01% 2998
2025
Q4 		$1.88K Sell
241
-104
-30% -$752 ﹤0.01% 3620
2025
Q3 		$2.62K Sell
345
-70
-17% -$583 ﹤0.01% 3379
2025
Q2 		$3.72K Sell
415
-374
-47% -$3.48K ﹤0.01% 3224
2025
Q1 		$5.92K Buy
789
+320
+68% +$2.58K ﹤0.01% 3015
2024
Q4 		$3.53K Buy
469
+124
+36% +$941 ﹤0.01% 3049
2024
Q3 		$2.62K Buy
345
+191
+124% +$1.45K ﹤0.01% 2981
2024
Q2 		$952 Buy
154
+46
+43% +$254 ﹤0.01% 3069
2024
Q1 		$549 Buy
108
+1
+0.9% +$6 ﹤0.01% 3091
2023
Q4 		$567 Buy
+107
New +$620 ﹤0.01% 2936

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

GAMMA Investing's BCRX Position: Q2 2026 in Review

GAMMA Investing increased its BioCryst Pharmaceuticals (BCRX) stake by 0.9% in Q2 2026, buying an estimated $99 and bringing the position to 1,229 shares worth $12.3K. The position accounts for ﹤0.01% of the portfolio, ranked #3102.

GAMMA Investing first reported a position in BCRX in Q4 2023 and has held it in 11 quarters since. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • GAMMA Investing held 1,229 shares of BioCryst Pharmaceuticals worth $12.3K as of Q2 2026.
  • GAMMA Investing bought 11 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $99.
  • BioCryst Pharmaceuticals made up ﹤0.01% of GAMMA Investing's portfolio in Q2 2026, its #3102 holding.
  • GAMMA Investing first reported a position in BioCryst Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.